Epigenetic therapy has had a significant impact on the management of haematologic malignancies. The aim of this study was to assess whether 5-aza-CdR and TSA inhibit the growth of leukaemia cells and induce caspase-3-dependent apoptosis by upregulating RUNX3 expression.
K562 and Reh cells were treated with 5-aza-CdR, TSA or both compounds. RT-PCR and Western blot analyses were used to examine the expression of RUNX3 at the mRNA and protein levels, respectively. Immunofluorescence microscopy was used to detect the cellular location of RUNX3. Additionally, after K562 cells were transfected with RUNX3, apoptosis and proliferation were studied using Annexin V staining and MTT assays.
The expression of RUNX3 in leukaemia cell lines was markedly less than that in the controls. Demethylating drug 5-aza-CdR could induce RUNX3 expression, but the combination of TSA and 5-aza-CdR had a greater effect than did treatment with a single compound. The combination of 5-aza-CdR and TSA induced the translocation of RUNX3 from the cytoplasm into the nucleus. TSA enhanced apoptosis induced by 5-aza-CdR, and Annexin V and Hoechst 33258 staining showed that the combination induced apoptosis but not necrosis. Furthermore, apoptosis was dependent on the caspase-3 pathway. RUNX3 overexpression in K562 cells led to growth inhibition and apoptosis and potentiated the effects of 5-aza-CdR induction.
RUNX3 plays an important role in leukaemia cellular functions, and the induction of RUNX3-mediated effects may contribute to the therapeutic value of combination TSA and 5-aza-CdR treatment.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Runt-related transcription factor 3
Cytosine phosphate guanine
Chronic myeloid leukaemia
Agirre X, Novo FJ, Calasanz MJ et al (2003a) TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. Mol Carcinog 38:201–208
Agirre X, Vizmanos JL, Calasanz MJ et al (2003b) Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. Oncogene 22:1070–1072
Bae SC, Takahashi E, Zhang YW, Ogawa E, Shigesada K, Namba Y, Satake M, Ito Y (1995) Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian Runt domain. Gene 159:245–248
Balmain A (2002) Cancer: new-age tumor suppressors. Nature 417:235–237
Bangsow C, Rubins N, Glusman G et al (2001) The RUNX3 gene-sequence structure and regulated expression. Gene 279:221–232
Banin S, Moyal L, Shieh S et al (1998) Enhanced phosphorylation of P53 by ATM in response to DNA damage. Science 281:1674–1677
Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis. Trends Genet 16:168–174
Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16:6–21
Bird AP, Wolffe AP (1999) Methylation-induced repression belts, braces, and chromatin. Cell 99:451–454
Chi KC, Margaret HLN (2008) Transcriptional repression of the gene RUNX3/AML2 by the t (8:21) and inv (16) fusion proteins in acute myeloid leukemia. Blood 112:3391–3402
Chi XZ, Yang JO, Kim WJ, Ito Y, Bae SC (2005) RUNX3 suppresses gastric epithelial cell growth by inducing P21WAP1/Cip1 expression in cooperation with TGF-β-activated SMAD. Mol Cell Biol 25:8097–8107
Claus R, Lubbert M (2003) Epigenetic targets in hematopoietic malignancies. Oncogene 22:6489–6496
Cordenonsi M et al (2007) Phosphorylation integration of TGF-ß and Ras/MAPK signaling through P53. Science 315:840–843
Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG (2000) E-cadherin expression is silenced by 5CpG island methylation in acute leukemia. Clin Cancer Res 6:4243–4248
Cornelius M, Rebekka G, Claudia M et al (2007) Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. PNAS 104:4594–4599
Dokmanovic M, Marks PA (2005) Prospects: histone deacetylase inhibitors. J Cell Biochem 96:293–304
Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457–463
el-Deiry WS, Tokino T, Velculescu VE et al (1993) WAF1, a potential mediator of P53 tumor suppression. Cell 75:817–825
Esteller M (2003) Profiling aberrant DNA methylation in hematologicneoplasms: a view from the tip of the iceberg. Clin Immunol 109:80–88
Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196:261–282
Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Ito Y (1999) Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Cpromoter. J Biol Chem 274:31577–31582
Harris CA, Eugane MJ (2001) BH3-only Bcl-2 family members are coordinately regulated by the JNK pathway and require Bax to induce apoptosis in neurons. J Biol Chem 276:37754–37760
Herman JG, Jen J, Merlo A, Baylin SB (1996) Hypermethylation-associated inactivation indicates a tumor suppressor role for p15 (INK4B). Cancer Res 56:722–727
Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57:837–841
Huang DC, Strasser A (2000) BH3-only proteins—essential initiators of apoptotic cell death. Cell 103:839–842
Inoue K, Ozaki S, Shiga T, Ito K, Masuda T, Okado N, Iseda T, Kudo N, Ito Y (2002) RUNX3 controls the axonal projection of proprioceptive dorsal root ganglion neurons. Nat Neurosci 5:946–954
Ito Y, Miyazono K (2003) RUNX transcription factors as key targets of TGF-β superfamily signaling. Curr Opin Genet Dev 13:43–47
Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Yeoh KG, Ito Y (2005) RUNX3, a novel tumor suppressor, is highly inactivated in gastric cancer by protein mislocalization. Cancer Res 65:7743–7750
Jahangeer S, Elliott RM, Henneberry RC (1982) β-Adrenergic receptor induction in HeLa cells: synergistic effect of 5-azacytidine and butyrate. Biochem Biophys Res Commun 108:1434–1440
Kosei I, Anthony C-BL, Manuel S-T et al (2008) RUNX3 attenuates β-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14:226–237
Krug U, Ganser A, Koeffler HP (2002) Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21:3475–3495
Li QL, Ito K, Sakakura C et al (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109:113–124
Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51
Mudit V, Joanna F (2009) Surfactant protein DNA methylation: a new entrant in the field of lung cancer diagnostics? Oncol Rep 21(1):3–21
Nickerson JA (2001) Experimental observations of a nuclear matrix. J Cell Sci 114:463–474
Okorokov AL, Rubbi CP, Metcalfe S, Milner J (2002) The interaction of P53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage. Oncogene 21:356–367
Puig-Kroger A, Corbi A (2006) RUNX3: a new player in myeloid gene expression and immune response. J Cell Biochem 98:744–756
Quesnel B, Guillerm G, Vereecque R et al (1998) Methylation of the p15 (INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985–2990
Sandhya P, Syed AA, Christopher D (2009) Subnuclear targeting of the RUNX3 tumor suppressor and its epigenetic association with mitotic chromosomes. J Cell Physiol 218:473–479
Takai D, Jones PA (2003) The CpG island searcher: a new WWW resource. In SilicoBiol 3:235–240
Wei D, Gong W, Oh SC et al (2005) Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res 65:4809–4816
Feng-Xian Zhai and Xiang-Fu Liu contributed equally to this work.
About this article
Cite this article
Zhai, F., Liu, X., Fan, R. et al. RUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines. J Cancer Res Clin Oncol 138, 439–449 (2012). https://doi.org/10.1007/s00432-011-1113-y
- Runt-related transcription factor 3 (RUNX3)
- Chronic myeloid leukaemia (CML)
- 5-aza-2-deoxycytidine (5-aza-CdR)
- TSA (trichostatin A)